Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Advertisement
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

Clinuvel Is Planning For US Commercialization Of Ultra-Orphan Drug Scenesse

Clinuvel's Scenesse for the ultra-rare, light-induced disease erythoropoietic protoporphyria (EPP) is already approved in Europe and the company is hopeful that a rolling NDA submission could pave the way for a US launch.

Rare Diseases Business Strategies

Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders

The rare disease specialist gained 10 gene therapy programs with the acquisition of Celenex, including two in clinical-stage development for Batten disease, in exchange for $100m up front. President Bradley Campbell talked to Scrip about the process that led to the deal and next steps for development.

Deals Rare Diseases

Clovis, CEO Mahaffy Settle SEC Investor Fraud Charges Over Rociletinib Efficacy Claims

Clovis, CEO Patrick Mahaffy and former CFO Erie Mast will pay more than $20m to settle charges by the SEC that the company misled investors on the efficacy of rociletinib. Clovis raised $298m in a public stock offering during the timeframe SEC says it misled investors.

Legal Issues Leadership

Pfizer Eyes First-To-Market Opportunity In Alopecia

Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.

Immune Disorders Research & Development

Deal Watch: Cigna Acquisition Of Express Scripts OKed By US Justice Dept.

It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.

Deals Business Strategies

Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio

Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.

Deals Research and Development Strategies
See All
Advertisement
UsernamePublicRestriction

Register